The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature.
Expert Rev Pharmacoecon Outcomes Res
; 21(4): 553-558, 2021 Aug.
Article
en En
| MEDLINE
| ID: mdl-33784935
ABSTRACT
Introduction:
To study the impact of biosimilars in assisted reproductive treatments, we performed a review of the literature. Biosimilars are a bioequivalent chemical drug referred to the original. Their production is strongly requested in order to reduce drug cost and reduce health economic impact on national health system. In assisted reproductive treatments different gonadotropin biosimilars are being produced.Areas covered For this reason, we performed a review of the literature on follitropin alfa Gonal-F biosimilar, Ovaleap and Bemfola, to assess their cost efficacy in national health system. Cost effective (CE) analysis and incremental cost-effectiveness ratio (ICER) were used as parameters for biosimilar impact evaluation in the national health system economy. In particular, they had only slight impact on cost reduction of recombinant follitropin alfa products in Europe.Expert opinion considering cost-effective analysis, Gonal-F remains the first choice for national health systems. However, well-designed powered methods are strongly needed to assess biosimilars cost-effectiveness.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Economía Farmacéutica
/
Hormona Folículo Estimulante Humana
/
Biosimilares Farmacéuticos
Tipo de estudio:
Health_economic_evaluation
Límite:
Humans
País como asunto:
Europa
Idioma:
En
Año:
2021
Tipo del documento:
Article